Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia
Primary Purpose
Dyslipidemia, Familial Hypercholesterolemia
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Lactobacillus paracasei B21060
low satured diet
Sponsored by
About this trial
This is an interventional treatment trial for Dyslipidemia
Eligibility Criteria
Inclusion Criteria:
- aged ≥ 6 and ≤ 12 years.
- Diagnosis of hypercholesterolemia (LDL cholesterol> 140 mg / dl)
- Each patient must have shown resistance to dietary therapy lasting at least 6-12 months.
Exclusion Criteria:
- Age <6 or> 12 years.
- Patients undergoing drug treatment for hypercholesterolemia.
- Any medical condition that may interfere with participation in this study
- Participation in clinical trials still in progress.
- Taking pre / probiotics for more than 7 days in the 6 months prior to enrollment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
diet plus Lactobacillus paracasei B21060
low saturated fats diet
Arm Description
low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
low saturated fats diet
Outcomes
Primary Outcome Measures
change of LDL cholesterol after 6 months of treatment wiyh symbiotic
Secondary Outcome Measures
Full Information
NCT ID
NCT02048410
First Posted
January 24, 2014
Last Updated
January 28, 2014
Sponsor
Federico II University
1. Study Identification
Unique Protocol Identification Number
NCT02048410
Brief Title
Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia
Official Title
Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federico II University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Probiotics have been proposed for the treatment of dyslipidemia. the investigators aimed to evaluate efficacy, tolerability and safety of a new symbiotic formulation containing a combination of probiotic and prebiotics and amine in the treatment of children affected by familial hypercholesterolemia (FH).
Detailed Description
FH subjects, aged 6-12 years, consecutively observed a Tertiary Center for Pediatric Nutrition were randomly allocated to two groups of intervention for 6 months: active group, received a low saturated fats diet plus the symbiotic (2.5×109cfu, bid) for 6 months; control group, received low saturated fats diet alone. All children received written indications for low saturated fats diet. The plasmatic lipid profile was assessed by peripheral blood sampling at T0 and T1.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyslipidemia, Familial Hypercholesterolemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
diet plus Lactobacillus paracasei B21060
Arm Type
Active Comparator
Arm Description
low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
Arm Title
low saturated fats diet
Arm Type
Placebo Comparator
Arm Description
low saturated fats diet
Intervention Type
Dietary Supplement
Intervention Name(s)
Lactobacillus paracasei B21060
Intervention Description
combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
Intervention Type
Other
Intervention Name(s)
low satured diet
Primary Outcome Measure Information:
Title
change of LDL cholesterol after 6 months of treatment wiyh symbiotic
Time Frame
The plasmatic lipid profile was assessed by peripheral blood sampling at enrollment and after 6 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
aged ≥ 6 and ≤ 12 years.
Diagnosis of hypercholesterolemia (LDL cholesterol> 140 mg / dl)
Each patient must have shown resistance to dietary therapy lasting at least 6-12 months.
Exclusion Criteria:
Age <6 or> 12 years.
Patients undergoing drug treatment for hypercholesterolemia.
Any medical condition that may interfere with participation in this study
Participation in clinical trials still in progress.
Taking pre / probiotics for more than 7 days in the 6 months prior to enrollment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto berni canani, MD,Phd
Organizational Affiliation
university of naples federicoII
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia
We'll reach out to this number within 24 hrs